Clinical and cost-effectiveness of the digital intervention, MyWay Diabetes, in people with type 2 diabetes living in Greater Manchester during the COVID-19 pandemic

PLOS ONE

卷:21

Research Article

Rathi Ravindrarajah¹  Matthew Gittins²  Luke Paterson³  Gabriel Rogers³  George Tilson²  Deborah J. Wake^4,5  Doogie Brodie⁴  Scott G. Cunningham^4,6  Naresh Kanumilli^7,8  Ewan Jones⁹  Peter Elton⁹  Nicola Milne⁸  Michael Morgan-Curran^10,11  Evangelos Kontopantelis^2,12  Thomas Allen^3,13  Martin K. Rutter^8,14 

[1] Greater Manchester & Eastern Cheshire Strategic Clinical Networks, Greater Manchester Health & Social Care Partnership, Manchester, United Kingdom

[2] Asclepius MedTech Limited, Leeds, United Kingdom

[3] Division of Diabetes, Endocrinology & Gastroenterology, School of Medical Sciences, University of Manchester, Manchester, United Kingdom

[4] My Way Digital Health, Dundee, United Kingdom

[5] Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom

[6] Northenden Group Practice, Manchester, United Kingdom

[7] Danish Centre for Health Economics, University of Southern Denmark, Odsense, Denmark

[8] Division of Informatics, Imaging and Data Science, School of Health Sciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester, United Kingdom

[9] Diabetes, Endocrinology & Metabolism Centre, Manchester Royal Infirmary, Manchester, United Kingdom

[10] Division of Nursing, Midwifery & Social Work, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom

[11] MyCognition Limited, Sheffield, United Kingdom

[12] Division of Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

[13] Manchester Centre for Health Economics, Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, United Kingdom

[14] Population Health & Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom

关键词: Diabetes mellitus;    Blood pressure;    Cholesterol;    HbA1c;    Type 2 diabetes;    Medical risk factors;    Cardiovascular disease risk;    Cardiology;   

DOI  :  10.1371/journal.pone.0349232

 received in 2025-08-13, accepted in 2026-04-27,  发布年份 2026

来源: PLOS

【 摘 要 】

AimsWe aimed to assess a) whether using the digital intervention, MyWay Diabetes (MWD), during the COVID-19 pandemic in Greater Manchester was associated with improvements in glycaemia and cardiovascular risk factors; and b) the cost-effectiveness of MWD.MethodsFrom 01st July 2019–30th April 2022, we assessed risk factor changes in MWD users (n = 507) with T2D, adjusting for changes in a matched control group of non-users (n = 10,135). Economic evaluation was conducted using United Kingdom Prospective Diabetes Study Outcomes Model version 2.1 simulating 1,000 patients over 40-years based on observed risk factor changes.ResultsOver 2-years follow-up, MWD use was associated with a clinically significant reductions in HbA1c of 3.1 (95%CI: 1.5 to 4.6) mmol/mol and decreases in systolic blood pressure (1.4 (0.2 to 2.6) mmHg) and cholesterol (0.1 (0.02 to 0.2) mmol/L) when compared to non-users. Including medication costs, MWD generated more health (0·015 QALYs) and lower costs (−£67 per person) compared to usual care. Excluding medication costs, MWD generated QALYs at a cost of £389 each, below the NICE threshold of £20,000–30,000/QALY.InterpretationAt population level, the risk factor changes associated with MWD are likely to reduce long-term diabetes-related complications risks and the intervention appears cost-effective.

【 授权许可】

CC BY   
Ravindrarajah et al 2026

【 图 表 】

Fig. 15

Fig. 1

Fig. 2